Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Latest news

Read or download our press releases for all latest news about our company, research & development activities and updates for investors. Consult our event calendar for an overview of conferences or meetings where you will be able to meet up with Oxurion associates. Be sure to check in regularly for the latest Oxurion press releases or just subscribe to our mailing list to receive regular updates.

Subscribe to our mailing list

30 Jun 2022
Regulated information - denominator
Information on the Total Number of Voting Rights (Denominator) following Conversion of Negma Convertible Bonds and Partial Reimbursement of Kreos/Pontifax Convertible Bonds

Leuven, BELGIUM, Boston, MA, US – June 30 , 2022 – 8.00 PM CET ...

13 Jun 2022
Event; THR-149; THR-687
Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting

Leuven, BELGIUM, Boston, MA, US – JUNE 13, 2022 – ...

7 Jun 2022
Event; THR-149
Oxurion Announces Preclinical Presentation on THR-149 at KININ2022

Leuven, BELGIUM, Boston, MA, US – JUNE 7, 2022  ...

3 Jun 2022
Event; THR-149; THR-687
Oxurion Announces Two Upcoming Presentations at The Macula Society 45th Annual Meeting

Leuven, BELGIUM, Boston, MA, US – JUNE 3, 2022  ...

1 Jun 2022
Event; Investors
Oxurion to Participate in Upcoming Investor Conferences

Leuven, BELGIUM, Boston, MA, US – June 1, 2022 – ...

31 May 2022
Regulated information - denominator
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA

Negma Group has converted 200 convertible bonds in Oxurion resulting in a EUR 500,000...

25 May 2022
Regulated information
Oxurion Announces Results of the Extraordinary Shareholders’ Meeting held on 24 May 2022

Leuven, Belgium, Boston, MA, US – May 25, 2022 – 07.00 PM CET –...

Archive

Media contact

Oxurion is committed and engaged to communicate openly with all of its stakeholders. For any media enquiries, comments or questions about Oxurion, please contact our Investor Relations & Corporate Communications team:

Gaston Geenslaan 1
B-3001 Heverlee
Belgium
Tel: +32 16 751 310

Info@oxurion.com